目的 探讨宁心宝胶囊联合美西律治疗室性早搏的临床疗效。方法 选取2022年2月—2023年11月北京市大兴区人民医院收治的室性早搏患者106例，按随机数字表法分为对照组和治疗组，每组各53例。对照组口服盐酸美西律片，4片/次，2次/d。在对照组基础上，治疗组口服宁心宝胶囊，2粒/次，3次/d。两组患者疗程均为4周。观察两组患者临床疗效，比较治疗前后两组患者室性早搏次数、室性早搏占总心搏比例，Myerburg分级评分和36项健康调查简表（SF-36）评分，心率变异性指标pNN50、全部相邻窦性R-R间期差值均方根值（rMSSD）和部窦性心搏R-R间期标准差（SDNN），心率震荡指标震荡斜率（TS）和TO，及中性粒细胞与淋巴细胞比值（NLR）和血清一氧化氮（NO）、白细胞介素-6（IL-6）水平。结果 治疗后，治疗组总有效率为92.45%，明显高于对照组77.36%（P＜0.05）。治疗后，两组患者室性早搏次数及占总心搏均明显低于同组治疗前（P＜0.05），且治疗后治疗组明显低于对照组（P＜0.05）。治疗后，两组Myerburg分级评分均小于治疗前，而SF-36评分均高于治疗前（P＜0.05），且治疗后治疗组患者评分明显好于对照组（P＜0.05）。治疗后，两组pNN50、rMSSD、SDNN、TS和血清NO水平均大于同组治疗前，而TO、NLR和血清IL-6浓度均低于治疗前（P＜0.05），且治疗后治疗组这些指标明显好于对照组（P＜0.05）。结论 宁心宝胶囊联合美西律治疗室性早搏，疗效和安全性较好，可有效稳定病情。

Objective To explore the clinical efficacy of Ningxinbao Capsules combined with mexiletide in treatment of ventricular premature beats. Methods Patients (106 cases) with ventricular premature beats in Beijing Daxing District People's Hospital from February 2022 to November 2023 were divided into control and treatment group by random number table method, and each group had 53 cases. Patients in the control group were po administered with Mexiletine Hydrochloride Tablets, 4 tablets/time, twice daily. Patients in the treatment group were po administered with Ningxinbao Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluations were evaluated, the number of premature ventricular contractions and the proportion of premature ventricular contractions to total heart rate, the scores of Myerburg grading and SF-36, heart rate variability and heart rate oscillation indicators pNN50, rMSSD, SDNN, TS and TO, the levels of NLR, NO and IL-6 in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 92.45%, which was significantly higher than that in the control group (77.36%, P < 0.05). After treatment, the number of ventricular premature beats and their proportion to total heart beats in two groups were significantly lower than before treatment in the same group (P < 0.05), and which in the treatment group were significantly lower than the control group (P < 0.05). After treatment, the Myerburg grading scores in two groups were lower than before treatment, while the SF-36 scores were higher than before treatment (P < 0.05), and the scores in the treatment group were significantly better than those in the control group after treatment (P < 0.05). After treatment, the pNN50, rMSSD, SDNN, TS and serum NO levels in two groups were higher than those in the same group before treatment, while the TO, NLR and serum IL-6 levels were lower (P < 0.05), and after treatment these indicators in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The combination of Ningxinbao Capsules and mexiletide is effective and safe in the treatment of ventricular premature beats. It can effectively stabilize the condition.

R972